

# Prof. ÖMER DİZDAR

## Personal Information

**Office Phone:** [+90 312 305 4330](tel:+903123054330)

**Email:** [omer.dizdar@hacettepe.edu.tr](mailto:omer.dizdar@hacettepe.edu.tr)

**Web:** <https://avesis.hacettepe.edu.tr/omer.dizdar>

**Address:** Hacettepe Üniversitesi Kanser Enstitüsü Prevanatif Onkoloji ABD, Altındağ, ANKARA

## International Researcher IDs

ORCID: 0000-0003-0911-9078

Yoksis Researcher ID: 58324

## Education Information

Postgraduate, Hacettepe University, Kanser Enstitüsü, Prevanatif Onkoloji Ad, Turkey 2015 - 2017

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi, İç Hastalıkları Abd Medikal Onkoloji Bölümü, Turkey 2005 - 2009

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, İç Hastalıkları Abd, Turkey 2000 - 2005

Undergraduate, Hacettepe University, Tıp Fakültesi (İng), Turkey 1994 - 2000

## Foreign Languages

English, C1 Advanced

## Dissertations

Postgraduate, Kronik periodontiti olan hastalarda kanser insidansının değerlendirilmesi, Hacettepe Üniversitesi, Kanser Enstitüsü, Prevanatif Onkoloji Ad, 2017

Expertise In Medicine, Aromataz inhibitörü kullanan meme kanserli hastalarda artralji sıklığı ve patogenezinin araştırılması, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Ad Tıbbi Onkoloji Bölümü, 2009

Expertise In Medicine, Multiple myelomalı hastalarda kemik tutulumunun belirlenmesinde kemik rezorbsiyon belirteçlerinin rolü, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Ad, 2005

## Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

## Academic Titles / Tasks

Professor, Hacettepe University, Kanser Enstitüsü, Prevanatif Onkoloji Ad, 2017 - Continues

## Academic and Administrative Experience

## Advising Theses

- DİZDAR Ö., Kanser tanısı alan hastaların birinci dereceden yakınlarında sigara bırakma davranışının değerlendirilmesi, Postgraduate, B.HÜSEYİN(Student), 2018
- DİZDAR Ö., Kolon kanseri ve tükürük mikrobiyom ilişkisi, Expertise In Medicine, D.CAN(Student), 2018
- DİZDAR Ö., Kolorektal kanser tanısı alan premenopozal kadınlarda adjuvan kemoterapiye bağlı amenore sıklığı ve ilişkili faktörlerin belirlenmesi, Expertise In Medicine, T.ŞAHİN(Student), 2017

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report**  
Guener N. I., DİZDAR Ö., Tuerker A., EKİNCİOĞLU A.  
ANTI-CANCER DRUGS, no.9, pp.878-881, 2024 (SCI-Expanded)
- II. **Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors**  
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., AKSOY S., ERMAN M., YALÇIN Ş.  
SUPPORTIVE CARE IN CANCER, no.7, 2024 (SCI-Expanded)
- III. **Acute heart failure following pazopanib treatment: a literature review featuring two case reports**  
KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.  
Anti-Cancer Drugs, vol.35, no.3, pp.302-304, 2024 (SCI-Expanded)
- IV. **The prognostic and predictive role of class III  $\beta$ -Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma**  
Sahin T., IŞIK A., Guven D., Ceylan F., BABAĞLU B., AKYOL A., YALÇIN S. S., DİZDAR Ö.  
Pancreatology, vol.24, no.2, pp.279-288, 2024 (SCI-Expanded)
- V. **Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)**  
BİLGIN E., Demirci Yıldırım T., Özdemir Ulusoy B., Ögüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., YILDIRIM R., Güven D. C., Akleylek C., Ediboğlu E., et al.  
Internal and Emergency Medicine, 2024 (SCI-Expanded)
- VI. **Sirolimus experience in adult patients with vascular malformations**  
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.  
Vascular, 2024 (SCI-Expanded)
- VII. **Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy**  
Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., GÜVEN D. C., YALÇIN Ş., DİZDAR Ö.  
International Journal of Clinical Oncology, 2024 (SCI-Expanded)
- VIII. **A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology**  
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.  
Irish Journal of Medical Science, vol.192, no.6, pp.2631-2634, 2023 (SCI-Expanded)
- IX. **The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey**  
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al.  
Medicine, vol.102, no.45, 2023 (SCI-Expanded)
- X. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer**

## **Patients with Iron-Deficiency Anemia**

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.

Current Oncology, vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)

- XI. **A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer**  
YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., YALÇIN Ş.  
Anti-cancer drugs, vol.34, no.10, pp.1190-1192, 2023 (SCI-Expanded)
- XII. **Molecularly imprinted electrochemical sensor for the selective and sensitive determination of octreotide in cancer patient plasma sample**  
Ozkan E., Ozcelikay G., Gök Topak E. D., NEMUTLU E., ÖZKAN S. A., DİZDAR Ö., AKSOY S., KIR S.  
Talanta, vol.263, 2023 (SCI-Expanded)
- XIII. **Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry**  
Duran E., Ozturk Z. O., BİLGİN E., BÜYÜKAŞIK Y., DİZDAR Ö., Yardimci G. K., Farisogullari B., ÖZSOY Z., AYAN G., Uzun G. S., et al.  
Rheumatology and Therapy, vol.10, no.4, pp.969-981, 2023 (SCI-Expanded)
- XIV. **Advances in the Early Detection of Hepatobiliary Cancers**  
YILDIRIM H. Ç., KAVGACI G., Chalabiyev E., DİZDAR Ö.  
Cancers, vol.15, no.15, 2023 (SCI-Expanded)
- XV. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.  
Anti-Cancer Drugs, vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)
- XVI. **SMART syndrome: a case report**  
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., Oguz K. K., DİZDAR Ö.  
ACTA NEUROLOGICA BELGICA, vol.123, no.3, pp.1137-1140, 2023 (SCI-Expanded)
- XVII. **Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data**  
Sütcüoğlu O., Doğan A., Yilmaz F., Şahin A. B., ŞAHİN T. K., Esen S. A., Erol C., ÜNER A., ÖZET A., Turan N., et al.  
Pancreas, vol.52, no.4, 2023 (SCI-Expanded)
- XVIII. **Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer**  
Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., Turker A., Hamaloglu E., KARAKOÇ D., Isik A., et al.  
Clinics and Research in Hepatology and Gastroenterology, vol.47, no.3, 2023 (SCI-Expanded)
- XIX. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**  
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.  
INTERNATIONAL JOURNAL OF CANCER, vol.152, pp.679-685, 2023 (SCI-Expanded)
- XX. **Emerging treatment strategies in hepatobiliary cancer**  
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.  
Expert Review of Anticancer Therapy, vol.23, no.3, pp.243-256, 2023 (SCI-Expanded)
- XXI. **Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment**  
Güven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., AKSOY S.  
Expert Review of Anticancer Therapy, vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded)
- XXII. **Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the**

**nosocomial infection rates in oncology wards**

GÜVEN D. C., EROĞLU İ., İsmayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL S., METAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded)

- XXIII. **Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer**  
YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.9, 2022 (SCI-Expanded)
- XXIV. **HER2-low breast cancer could be associated with an increased risk of brain metastasis**  
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMHEMETOĞLU K., KERTMEN N., DİZDAR Ö., ÜNER A., AKSOY S.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.2, pp.332-339, 2022 (SCI-Expanded)
- XXV. **The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study**  
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., KERTMEN N., DİZDAR Ö., AKSOY S.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded)
- XXVI. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**  
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C., Olgun P., KERTMEN N., DİZDAR Ö., et al.  
FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
- XXVII. **Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment**  
Güven D. C., Taban H., Dizdar O.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.1, pp.203-204, 2022 (SCI-Expanded)
- XXVIII. **Correlation Between THSD7A Expression and Tumor Characteristics of Azoxy methane-Induced Colon Cancer Model in Rats**  
AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., ÖZERCAN İ. H., DİZDAR Ö., YALÇIN Ş.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded)
- XXIX. **A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer**  
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.  
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.168, 2021 (SCI-Expanded)
- XXX. **The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors**  
Güven D. C., Aktepe O. H., Aksun M. S., Sahin T. K., Kavgaci G., Ucgul E., Cakir I. Y., Yildirim H. C., Guner G., Akin S., et al.  
ANNALS OF ONCOLOGY, vol.32, 2021 (SCI-Expanded)
- XXXI. **The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy**  
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİK TEN B., Yeter H. H., YÜCE D., DİZDAR Ö., ERMAN M.  
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.10, pp.1957-1963, 2021 (SCI-Expanded)
- XXXII. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**  
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., İncesu F. G. G., TAHİLLİOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XXXIII. **Sarcopenia and anthracycline cardiotoxicity in patients with cancer**  
BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., BARIŞTA İ., GÜNER G., GÜVEN D. C., KERTMEN N., et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XXXIV. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**  
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö.,

- AKSOY S., et al.  
BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)
- XXXV. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**  
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.  
SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)
- XXXVI. **PILE: a candidate prognostic score in cancer patients treated with immunotherapy**  
Güven D. C., Yildirim H. C., Bilgin E., Aktepe O. H., Taban H., Sahin T. K., Cakir I. Y., Akin S., Dizdar O., Aksoy S., et al.  
CLINICAL & TRANSLATIONAL ONCOLOGY, vol.23, no.8, pp.1630-1636, 2021 (SCI-Expanded)
- XXXVII. **Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report**  
GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.5, pp.1281-1283, 2021 (SCI-Expanded)
- XXXVIII. **THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (SCI-Expanded)
- XXXIX. **Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data**  
Ozdemir N., DİZDAR Ö., YAZICI O., AKSOY S., Dede D. S., Budakoglu B., METAN G., ALP A., BUDAKOĞLU I. İ., Oksuzoglu O. B. C., et al.  
INTERNATIONAL JOURNAL OF CANCER, vol.148, no.10, pp.2407-2415, 2021 (SCI-Expanded)
- XL. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.  
SUPPORTIVE CARE IN CANCER, vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded)
- XLI. **Comments on "Survival impact of adjuvant chemotherapy in patients with stageIIA colon cancer: Analysis of the National Cancer Database"**  
DİZDAR Ö.  
INTERNATIONAL JOURNAL OF CANCER, vol.148, no.4, pp.1027, 2021 (SCI-Expanded)
- XLII. **What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis**  
Aktas B. Y., Degirmenciler R. F., Durmaz C. D., Taban H., Guven D. C., Guner G., Yildirim H. C., Demir M., Kertmen N., Arik Z., et al.  
ANNALS OF ONCOLOGY, vol.32, 2021 (SCI-Expanded)
- XLIII. **Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer**  
Efil S. C., Guner G., Guven D. C., Celikten B., Celebiyev E., Taban H., Akyol A., Kilickap S., YALÇIN S. S., Dizdar O.  
ANNALS OF ONCOLOGY, vol.32, 2021 (SCI-Expanded)
- XLIV. **Cancer incidence in Behcet's disease**  
GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEK B., AKTAŞ B. Y., KİRAZ S., Gullu I., KARADAĞ Ö., DİZDAR Ö.  
IRISH JOURNAL OF MEDICAL SCIENCE, vol.189, no.4, pp.1209-1214, 2020 (SCI-Expanded)
- XLV. **Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives**  
C Guven D., ŞAHİN T. K., DİZDAR Ö., KILIÇKAP S.  
BIOMARKERS IN MEDICINE, vol.14, pp.1383-1392, 2020 (SCI-Expanded)
- XLVI. **All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past**  
Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.43, no.9, pp.676, 2020 (SCI-Expanded)
- XLVII. **Cancer incidence in Behcet's Disease.**

- Güven D. C., Bolek E. C., Altıntop S. E., Celikten B., Aktas B. Y., Kiraz S., Gullu I. H., Karadag O., Dizdar O.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (SCI-Expanded)
- XLVIII. **Complete responses to two different anti-PD1 agents in a metastatic melanoma patient**  
KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.496-499, 2020 (SCI-Expanded)
- XLIX. **Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer**  
GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.1, pp.256-258, 2020 (SCI-Expanded)
- L. **The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer**  
Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., Kaseb A. O., YALÇIN Ş.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.2, pp.94-102, 2020 (SCI-Expanded)
- LI. **Classifying sarcopenia: using median value or cut-off values?**  
BAŞ O., DİZDAR Ö.  
BREAST CANCER RESEARCH AND TREATMENT, vol.176, no.2, pp.479, 2019 (SCI-Expanded)
- LII. **Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy**  
AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.  
EXPERT REVIEW OF ANTICANCER THERAPY, vol.19, no.7, pp.589-601, 2019 (SCI-Expanded)
- LIII. **Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability**  
KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.6, pp.1195-1196, 2019 (SCI-Expanded)
- LIV. **Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia**  
BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., KARDAŞ R. C., YILDIRIM T., Hayran M. K., KALYONCU U., et al.  
Rheumatology International, vol.39, no.6, pp.1045-1051, 2019 (SCI-Expanded)
- LV. **Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients**  
Güven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., Lacin S., Karakas Y., KILIÇKAP S., Hayran M., et al.  
BIOMARKERS IN MEDICINE, vol.13, no.9, pp.725-735, 2019 (SCI-Expanded)
- LVI. **The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy**  
ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., ŞENDUR M. A. N., Bilgin B., DEMİR M., BOZBULUT U. B., et al.  
ANTI-CANCER DRUGS, vol.30, no.3, pp.289-294, 2019 (SCI-Expanded)
- LVII. **Evaluation of cancer risk in patients with periodontal diseases**  
Güven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., Baspinar B., Akbiyik I., AKTAŞ B. Y., YÜCE D., et al.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.3, pp.826-831, 2019 (SCI-Expanded)
- LVIII. **Noninferiority for Short-HER or short-chemotherapy?**  
Aktas B. Y., Guven D. C., Dizdar O.  
ANNALS OF ONCOLOGY, vol.30, no.1, pp.147, 2019 (SCI-Expanded)
- LIX. **Glucocorticoids in breast cancer treatment: real benefit or selection bias?**  
Guner G., DİZDAR Ö.  
BREAST CANCER RESEARCH AND TREATMENT, vol.172, no.1, pp.243, 2018 (SCI-Expanded)
- LX. **When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis**  
Karakas Y., Vural S., DIKER O., DİZDAR Ö.  
DERMATOLOGIC THERAPY, vol.31, no.6, 2018 (SCI-Expanded)
- LXI. **EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**

- HAYRAN K. M., Yuce D., Kilickap S., Dizdar O., Huseyin B., Erman M., Celik I.  
VALUE IN HEALTH, vol.21, 2018 (SCI-Expanded)
- LXII. **TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY AND RELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**  
HAYRAN K. M., Yuce D., Kilickap S., Huseyin B., Erman M., Dizdar O., Celik I.  
VALUE IN HEALTH, vol.21, 2018 (SCI-Expanded)
- LXIII. **The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival**  
KARAKAS Y., DİZDAR Ö., AKSOY S., Hayran M., Altundag K.  
CLINICAL BREAST CANCER, vol.18, no.4, pp.320-327, 2018 (SCI-Expanded)
- LXIV. **Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey**  
ESİN E., YILDIZ F., Lacin S., KARAKAS Y., GÜLTEKİN M., DİZDAR Ö., YALÇIN Ş.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.411-418, 2018 (SCI-Expanded)
- LXV. **Familial Mediterranean fever: new insights into cancer immunoprevention? Comment on the article by Brenner et al**  
BİLGİN E., Erden A., DİZDAR Ö.  
ARTHRITIS & RHEUMATOLOGY, vol.70, no.7, pp.1167, 2018 (SCI-Expanded)
- LXVI. **Factors associated with quitting action following smoking cessation counseling.**  
Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYİN B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- LXVII. **Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma**  
AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.  
CURRENT PROBLEMS IN CANCER, vol.42, no.3, pp.344-349, 2018 (SCI-Expanded)
- LXVIII. **Fusobacterium and colorectal carcinogenesis**  
Güven D. C., DİZDAR Ö.  
CARCINOGENESIS, vol.39, no.1, pp.84, 2018 (SCI-Expanded)
- LXIX. **Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms**  
AKIN S., DİZDAR Ö., Hayran M.  
ANNALS OF SURGICAL ONCOLOGY, vol.24, 2017 (SCI-Expanded)
- LXX. **Tumor Sidedness and Prognosis in Colorectal Cancer: Is Microbiome the Missing Link?**  
KARAKAS Y., DİZDAR Ö.  
JAMA ONCOLOGY, vol.3, no.7, pp.1000, 2017 (SCI-Expanded)
- LXXI. **Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database**  
DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.  
JOURNAL OF BUON, vol.22, no.2, pp.530-534, 2017 (SCI-Expanded)
- LXXII. **Increased cancer risk in patients with periodontitis**  
DİZDAR Ö., HAYRAN M., Güven D. C., YILMAZ T. B., TAHERİ S., AKMAN A. C., BİLGİN E., HUSEYİN B., BERKER E.  
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.12, pp.2195-2200, 2017 (SCI-Expanded)
- LXXIII. **Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience**  
Ateş O., Aksoy S., Yeter H. H., Sunar V., Kertmen N., Dizdar O., Turker A., Kars A.  
INDIAN JOURNAL OF CANCER, vol.54, no.1, pp.321-325, 2017 (SCI-Expanded)
- LXXIV. **Vaccination perception and attitudes among patients with cancer receiving chemotherapy**  
AKIN Ş., DİZDAR Ö., Karakas Y., ÖZİŞİK L., Tanriover M. D., Kamisli S., ERMAN M., HAYRAN K. M.  
ANNALS OF ONCOLOGY, vol.27, 2016 (SCI-Expanded)
- LXXV. **Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes**  
Kucukoztas N., OĞUZ A., Rahatli S., Altundag O., Altundag K.  
JOURNAL OF BUON, vol.21, no.5, pp.1076-1081, 2016 (SCI-Expanded)
- LXXVI. **Interpretation of survival data: which graphical analysis is appropriate?**  
Dizdar O., AKIN S., HAYRAN M.

- THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol.8, no.4, pp.312, 2016 (SCI-Expanded)
- LXXVII. **Analysis of the Adjuvant Hormone Therapy Randomized Trial**  
Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.34, no.17, pp.2070-2071, 2016 (SCI-Expanded)
- LXXVIII. **Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer**  
Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E., OZGU E., TERZIOGLU S. G., GUNGOR T.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.2, pp.110-115, 2016 (SCI-Expanded)
- LXXIX. **Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy**  
AKIN S., DİZDAR Ö., ÖZİŞİK L., TANRIOVER M., KAMISLI S., ERMAN M., HAYRAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.167-172, 2016 (SCI-Expanded)
- LXXX. **Advances in PARP inhibitors for the treatment of breast cancer**  
DİZDAR Ö., Arslan C., ALTUNDAG K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.16, no.18, pp.2751-2758, 2015 (SCI-Expanded)
- LXXXI. **Is Dexamethasone a Better Partner for Abiraterone Than Prednisolone?**  
Dizdar O.  
ONCOLOGIST, vol.20, no.5, 2015 (SCI-Expanded)
- LXXXII. **The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients**  
BABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., Petekkaya I., Altundag K.  
JOURNAL OF BUON, vol.20, no.1, pp.50-56, 2015 (SCI-Expanded)
- LXXXIII. **Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update**  
Arslan C., Dizdar O., ALTUNDAG K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.15, no.12, pp.1643-1658, 2014 (SCI-Expanded)
- LXXXIV. **Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone**  
RAHATLI S., DİZDAR Ö., KÜÇÜKÖZTAŞ N., OĞUZ A., YALÇIN S., ÖZEN Ö., Reyhan N. H., TARHAN N. Ç., YILDIZ F., DURSUN P., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.9, pp.3891-3893, 2014 (SCI-Expanded)
- LXXXV. **Tertiary Cancer Center Experience: Pregnancy-Associated Breast Cancer**  
Kuzas T. Y., Koca E., BABACAN T., Turkbeyler I. H., Sarici F., Altundag K.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.4, pp.284-285, 2014 (SCI-Expanded)
- LXXXVI. **Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy**  
OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., PEKTAS G., SEKER M. M., AKSOY S., Arslan C., et al.  
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.31, no.8, pp.1709-1715, 2013 (SCI-Expanded)
- LXXXVII. **Outcomes of locally advanced breast cancer patients with  $\geq 10$  positive axillary lymph nodes**  
KOCA E., KUZAN T. Y., Dizdar O., Babacan T., SAHIN I., ARARAT E., ALTUNDAG K.  
MEDICAL ONCOLOGY, vol.30, no.3, 2013 (SCI-Expanded)
- LXXXVIII. **Breast cancer in octogenarian women: clinical characteristics and outcome**  
Kuzan T. Y., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S., et al.  
JOURNAL OF BUON, vol.18, no.2, pp.328-334, 2013 (SCI-Expanded)
- LXXXIX. **Association of breast cancer subtypes and body mass index**  
Petekkaya I., ŞAHİN U., Gezgen G., Solak M., YÜCE D., DİZDAR Ö., ARSLAN Ç., Ayyildiz V., Altundag K.  
TUMORI J, vol.99, no.2, pp.129-133, 2013 (SCI-Expanded)
- XC. **Frequency of thyroid disease among breast cancer patients: a descriptive study of breast cancer patients**  
Vural O., Dizdar O., Petekkaya I., Alnak A., Babacan T., Altundag K.  
JOURNAL OF BUON, vol.18, no.1, pp.294-295, 2013 (SCI-Expanded)
- XCI. **Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature**



- Koca E., Kuzan T. Y., BABACAN T., Turkbeyler I. H., Sarici F., Altundag K.  
BREAST CARE, vol.8, no.6, pp.453-454, 2013 (SCI-Expanded)
- XCII. **Impact of Treatment Strategies on Local Control and Survival in Uterine Carcinosarcomas in Turkey**  
Kucukoztas N., Dizdar O., Rahatli S., Dursun P., Yalcin S., Altundag O., Ozen O., Reyhan N. H., Tarhan C., YILDIZ F., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.5, pp.2959-2962, 2013 (SCI-Expanded)
- XCIII. **Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor**  
Kuria I. M., Petekkaya I., Hasanov E., Babacan T., Dizdar O., Altundag K.  
JOURNAL OF BUON, vol.17, no.4, pp.798-799, 2012 (SCI-Expanded)
- XCIV. **Neuromyotonia forerunning the diagnosis of an eventual thymoma**  
Ozcakar L., Ozcan H. N., Dizdar O., Karaoglanoglu N., Tan E.  
EUROPEAN JOURNAL OF NEUROLOGY, vol.19, no.9, 2012 (SCI-Expanded)
- XCIV. **Frequency of HCV infection in renal cell carcinoma patients**  
Budakoglu B., Aksoy S., ARSLAN Ç., Uyeturk U., Babacan N. A., Ozcan M. F., Yildiz R., Oven B. B., Ozdemir N. Y., Dizdar O., et al.  
MEDICAL ONCOLOGY, vol.29, no.3, pp.1892-1895, 2012 (SCI-Expanded)
- XCVI. **Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain**  
Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.  
ONKOLOGIE, vol.35, no.5, pp.254-258, 2012 (SCI-Expanded)
- XCVII. **Breast cancer subtypes and outcomes of central nervous system metastases**  
Arslan U. Y., Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., DİZDAR Ö., Altundag K., Alkis N., Zengin N.  
BREAST, vol.20, no.6, pp.562-567, 2011 (SCI-Expanded)
- XCVIII. **Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer**  
BULUT N., AKSOY S., DİZDAR Ö., Dede D. S., Arslan C., DOĞAN E., Gullu I., Ozisik Y., Altundag K.  
MEDICAL ONCOLOGY, vol.28, 2011 (SCI-Expanded)
- XCIX. **Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response**  
ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., Gullu I., Altundag K.  
TUMORI, vol.97, no.6, pp.711-716, 2011 (SCI-Expanded)
- C. **Vitamin D intake may be effective in the management of triple-negative breast cancer**  
Harputluoglu H., Dizdar O., Karaahmet F., Altundag K.  
JOURNAL OF BUON, vol.16, no.3, pp.569, 2011 (SCI-Expanded)
- CI. **Pure mucinous carcinoma of the breast: a single center experience**  
Dogan E., Aksoy S., Dizdar O., Arslan C., Dede D. S., Ozisik Y., Altundag K.  
JOURNAL OF BUON, vol.16, no.3, pp.565-567, 2011 (SCI-Expanded)
- CII. **Nilotinib is Effective in Imatinib and Sunitinib Resistant GIST: A Case Report**  
DİZDAR Ö., YALÇIN Ş.  
HEPATO-GASTROENTEROLOGY, vol.58, no.107, pp.859-860, 2011 (SCI-Expanded)
- CIII. **Clinicopathologic features of patients with breast cancer under treatment of bisphosphonate at the time of diagnosis: Retrospective analysis**  
Dede D. S., Arslan C., Aksoy S., Dizdar O., Dogan E., Alkan A., Gullu I. H., Ozisik Y. Y., Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CIV. **Frequency of HCV infection in renal cell carcinoma patients**  
Budakoglu B., Aksoy S., Arslan C., Uyeturk U., Babacan N. A., Ozcan M. F., Yildiz R., Oven B. B., Ozdemir N., Dizdar O., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- CV. **Clinical and pathological characteristics of very young breast cancer patients ( $\leq$  25 years of age)**  
Ararat E., Sahin I., Arslan C., Aksoy S., Dizdar O., Ozisik Y., Altundag K.  
JOURNAL OF BUON, vol.16, no.2, pp.372, 2011 (SCI-Expanded)

- CVI. **Percentage of family history of cancer in patients with breast cancer: Is it changing with ethnicity?**  
Dizdar O., Arslan C., Altundag K.  
JOURNAL OF BUON, vol.16, no.2, pp.373, 2011 (SCI-Expanded)
- CVII. **Zoledronic acid and atrial fibrillation in cancer patients**  
ARSLAN Ç., AKSOY S., DİZDAR Ö., Dede D. S., HARPUTLUOĞLU H., ALTUNDAĞ M. K.  
SUPPORTIVE CARE IN CANCER, vol.19, no.3, pp.425-430, 2011 (SCI-Expanded)
- CVIII. **Ipsilateral Breast Cancer in a Patient with Poland's Syndrome**  
Yesilkaya Y., DİZDAR Ö., Altundag K.  
AMERICAN SURGEON, vol.77, no.2, pp.234-235, 2011 (SCI-Expanded)
- CIX. **Malignancies after rituximab treatment: just coincidence or more?**  
Aksoy S., Arslan C., Harputluoglu H., Dizdar O., Altundag K.  
JOURNAL OF BUON, vol.16, no.1, pp.112-115, 2011 (SCI-Expanded)
- CX. **Other malignancies in patients with breast cancer: a single institute experience**  
Dogan E., AKSOY S., DİZDAR Ö., ŞENER DEDE D., ARSLAN Ç., Ozisik Y., Altundag K.  
MEDICAL ONCOLOGY, vol.27, no.4, pp.1434-1435, 2010 (SCI-Expanded)
- CXI. **Blood ABO groups and risk of breast cancer**  
ŞENER DEDE D., AKSOY S., DİZDAR Ö., Cerci P., Gullu I., Ozisik Y., Altundag K.  
MEDICAL ONCOLOGY, vol.27, no.4, pp.1433, 2010 (SCI-Expanded)
- CXII. **Two Important Determinants May Play a Role in the Success of the FinHer Trial**  
Isik M., DİZDAR Ö., Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.20, 2010 (SCI-Expanded)
- CXIII. **Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates**  
AKSOY S., DİZDAR Ö., Altundag K.  
MEDICAL ONCOLOGY, vol.27, no.2, pp.568, 2010 (SCI-Expanded)
- CXIV. **Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?**  
Aksoy S., Arslan C., Kurt M., Dizdar O., Dede D. S., Dogan E., Gullu I. H., Ozisik Y. Y., Altundag M. K., Guler N.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXV. **Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain**  
Dizdar O., Altundag M. K., Ozkok S., Ozsaran Z., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXVI. **Systemic treatment in breast-cancer patients with brain metastasis**  
Arslan C., DİZDAR Ö., Altundag K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.11, no.7, pp.1089-1100, 2010 (SCI-Expanded)
- CXVII. **Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution.**  
Surmell Z. G., Aksoy S., Dizdar O., Dede D. S., Dogan E., Arslan C., Gullu I. H., Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXVIII. **Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.**  
Ozen M., Aksoy S., Dizdar O., Dede D. S., Dogan E., Arslan C., Gullu I. H., Altundag M. K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded)
- CXIX. **Clinical and pathological characteristics of breast cancer patients with history of tonsillectomy**  
Isik M., AKSOY S., Dede D. S., DİZDAR Ö., Kara A., Gullu I., Ozisik Y., Altundag K.  
BREAST, vol.19, no.2, pp.152, 2010 (SCI-Expanded)
- CXX. **Skin metastasis of ovarian cancer: a rare entity**  
Arslan C., Dede D. S., Dizdar O., Altundag K.  
JOURNAL OF BUON, vol.15, no.2, pp.398-399, 2010 (SCI-Expanded)
- CXXI. **Synchronous Ovarian Cancer in a Patient with Pleomorphic Lobular Breast Cancer: A Therapeutic Dilemma**

- Dizdar O, Arslan C., Altundag K.  
CLINICAL ONCOLOGY, vol.22, no.2, pp.153-154, 2010 (SCI-Expanded)
- CXXII. **Clinical and pathological characteristics of breast cancer patients with history of cesarean delivery**  
Kalan I, Turgut D., AKSOY S., ŞENER DEDE D., DİZDAR Ö., Ozisik Y., Altundag K.  
BREAST, vol.19, no.1, pp.67-68, 2010 (SCI-Expanded)
- CXXIII. **Estrogen receptor immunohistochemistry cutoff value: Standardization is needed**  
ARSLAN Ç., DİZDAR Ö., Altundag K.  
HUMAN PATHOLOGY, vol.41, no.1, pp.150, 2010 (SCI-Expanded)
- CXXIV. **Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia**  
DİZDAR Ö., Oezcakar L., Malas F. U., HARPUTLUOĞLU H., Bulut N., Aksoy S., Ozisik Y., Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.30, pp.4955-4960, 2009 (SCI-Expanded)
- CXXV. **Chemotherapy in Older Women with Breast Cancer**  
DİZDAR Ö., ŞENER DEDE D., Altundag K.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.361, no.10, pp.1023, 2009 (SCI-Expanded)
- CXXVI. **Pharmacotherapy of triple-negative breast cancer**  
ARSLAN Ç., DİZDAR Ö., Altundag K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.10, no.13, pp.2081-2093, 2009 (SCI-Expanded)
- CXXVII. **Reproductive and Hormonal Risk Factors for Postmenopausal Luminal, HER-2-overexpressing, and Triple-negative Breast Cancer**  
DİZDAR Ö., AKSOY S., Altundag K.  
CANCER, vol.115, no.8, pp.1802, 2009 (SCI-Expanded)
- CXXVIII. **Pathological characteristics of very young ( $\leq 30$  years) breast cancer patients: a single-institution experience from Turkey**  
Aksoy S., Bulut N., Dizdar O., Tosur M., Meral A., Altundag K.  
ANNALS OF ONCOLOGY, vol.20, no.4, pp.790, 2009 (SCI-Expanded)
- CXXIX. **Emerging drugs in metastatic breast cancer**  
DİZDAR Ö., Altundag K.  
EXPERT OPINION ON EMERGING DRUGS, vol.14, no.1, pp.85-98, 2009 (SCI-Expanded)
- CXXX. **Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation**  
KALYONCU U., DİZDAR Ö., Duman A. E., KARADAĞ Ö., TUFAN A., Yucel O., Tayfur O., Sen D., Ülger Z., KEPEZ A., et al.  
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, no.1, pp.103-108, 2009 (SCI-Expanded)
- CXXXI. **Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?**  
Dizdar O., Aksoy S., Altundag K.  
ANNALS OF ONCOLOGY, vol.20, no.1, pp.189, 2009 (SCI-Expanded)
- CXXXII. **Prognostic factors in long-term breast cancer survivors with brain metastases**  
Harputluoglu H., Kara A., DİZDAR Ö., Surmeli Z. G., Altundag K.  
BREAST CANCER RESEARCH AND TREATMENT, vol.112, no.1, pp.215, 2008 (SCI-Expanded)
- CXXXIII. **Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment**  
AKSOY S., DİZDAR Ö., Altundag K.  
BREAST, vol.17, no.5, pp.433-435, 2008 (SCI-Expanded)
- CXXXIV. **Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors**  
Harputluoglu H., DİZDAR Ö., Karaahmet F., Altundag K.  
BREAST CANCER RESEARCH AND TREATMENT, vol.110, no.3, pp.541, 2008 (SCI-Expanded)
- CXXXV. **Weekly paclitaxel in the adjuvant treatment of breast cancer**  
AKSOY S., DİZDAR Ö., Altundag K.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.359, no.3, pp.310, 2008 (SCI-Expanded)
- CXXXVI. **A case report: zoledronic acid-induced anterior uveitis**  
KILIÇKAP S., Ozdamar Y., ALTUNDAĞ M. K., DİZDAR Ö.  
MEDICAL ONCOLOGY, vol.25, no.2, pp.238-240, 2008 (SCI-Expanded)

- CXXXVII. **Clinicopathologic evaluation of non-Hodgkin lymphoma (NHL): A single centre experience**  
 Kilickap S., Barista I., Turkmen E., Dizdar O., Aksoy S., Turker A., Gullu I., Ozisik Y., Kars A., Tekuzman G.  
 JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- CXXXVIII. **Characteristics of breast cancer patients with central nervous system metastases: A single-center experience**  
 Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S., Ozisik Y., Guler N., BARIŞTA İ., Gullu I., Hayran M., et al.  
 JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.100, no.5, pp.521-526, 2008 (SCI-Expanded)
- CXXXIX. **Prognostic impact of bone turnover markers in multiple myeloma**  
 Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., Hascelik G., Cila A., Pinar A., Tekuzman G.  
 JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- CXL. **Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer**  
 DİZDAR Ö., Bulut N., Altundag K.  
 BREAST CANCER RESEARCH AND TREATMENT, vol.109, no.2, pp.403, 2008 (SCI-Expanded)
- CXLI. **Aromatase inhibitor-associated arthralgia: Prevalence, clinical and serum parameters among Turkish postmenopausal breast cancer patients**  
 Harputluoglu H., Dizdar O., Malas F. U., Ozcakar L., Bulut N., Ozisik Y., Altundag K.  
 JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- CXLII. **Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C**  
 DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ.  
 EUROPEAN JOURNAL OF HAEMATOLOGY, vol.80, no.5, pp.381-385, 2008 (SCI-Expanded)
- CXLIII. **Prognostic factors in breast cancer patients with brain metastases**  
 Harputluoglu H., DİZDAR Ö., Altundag K.  
 JOURNAL OF NEURO-ONCOLOGY, vol.87, no.2, pp.193, 2008 (SCI-Expanded)
- CXLIV. **Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer**  
 DİZDAR Ö., Bulut N., Altundag K.  
 BREAST, vol.17, no.2, pp.120, 2008 (SCI-Expanded)
- CXLV. **Efficacy of chemotherapy for brain metastases from breast carcinoma: In regard to Le Scodan et al. (Int J Radia T Oncol Biol Phys 2007;69 : 839-845)**  
 DİZDAR Ö., Tapan U., Altundag K.  
 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.70, no.5, pp.1615, 2008 (SCI-Expanded)
- CXLVI. **Erectile dysfunction in successfully treated lymphoma patients**  
 AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., Ozen H., ERMAN M., ÇELİK İ.  
 SUPPORTIVE CARE IN CANCER, vol.16, no.3, pp.291-297, 2008 (SCI-Expanded)
- CXLVII. **Familial chemosensitivity test: Can it be a predictive factor in the management of familial breast cancer?**  
 DİZDAR Ö., Harputluoglu H., Altundag K.  
 BREAST, vol.17, no.1, pp.5, 2008 (SCI-Expanded)
- CXLVIII. **Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer**  
 Bulut N., Harputluoglu H., Dizdar O., Altundag K.  
 JOURNAL OF NEURO-ONCOLOGY, vol.86, no.2, pp.241, 2008 (SCI-Expanded)
- CXLIX. **Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines**  
 DİZDAR Ö., ŞENER DEDE D., Bulut N., Altundag K.  
 BREAST CANCER RESEARCH AND TREATMENT, vol.107, no.2, pp.303, 2008 (SCI-Expanded)
- CL. **Vitamin D intake and breast cancer risk in postmenopausal women**  
 Dizdar O., Harputluoglu H., Altundag K.  
 ARCHIVES OF INTERNAL MEDICINE, vol.167, no.22, pp.2532, 2007 (SCI-Expanded)
- CLI. **Potential targeted therapy options in the management of basal cell subtype of breast carcinoma**

- Harputluoglu H., DİZDAR Ö., Altundag K.  
HUMAN PATHOLOGY, vol.38, no.12, pp.1869, 2007 (SCI-Expanded)
- CLII. **Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer**  
DİZDAR Ö., Harputluoglu H., Altundag K.  
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.69, no.5, pp.1651, 2007 (SCI-Expanded)
- CLIII. **Bone mineral density in breast cancer patients with estrogen receptor-negative tumor**  
Dede D. S., Dizdar O., Harputluoglu H., Altundag K.  
MATURITAS, vol.58, no.3, pp.324, 2007 (SCI-Expanded)
- CLIV. **Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience**  
Aksoy S., Dizdar O., Harputluoglu H., Altundag K.  
ANNALS OF ONCOLOGY, vol.18, no.11, pp.1904-1906, 2007 (SCI-Expanded)
- CLV. **Appropriate utilization of hospital beds in internal medicine: evaluation in a tertiary care hospital**  
Dizdar O., Karadag O., Kalyoncu U., Kurt M., ULGER Z., SARDAN Y. C., Unal S.  
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, vol.13, no.3, pp.408-411, 2007 (SCI-Expanded)
- CLVI. **Rituximab-induced viral infections in lymphoma patients**  
Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., Barista I.  
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- CLVII. **Predictive factors for metastasis in patients (pts) with gastric cancer**  
Kilickap S., Dizdar O., Harputluoglu H., Aksoy S., YALÇIN S. S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (SCI-Expanded)
- CLVIII. **Research for bleeding tendency in patients presenting with significant epistaxis**  
Dizdar O., Onal I. K., Ozakin E., Karakilic E., Karadag O., Kalyoncu U., Coskun F., Buyukasik Y.  
BLOOD COAGULATION & FIBRINOLYSIS, vol.18, no.1, pp.41-43, 2007 (SCI-Expanded)
- CLIX. **Macrophage inflammatory protein-1 alpha: A link between innate immunity and familial mediterranean fever?**  
Dizdar O., Kalyoncu U., Karadag O., Akdogan A., Kiraz S., Ertenli I., Barista I., Calguneri M.  
CYTOKINE, vol.37, no.1, pp.92-95, 2007 (SCI-Expanded)
- CLX. **Rituximab-related viral infections in lymphoma patients**  
Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., Barista I.  
LEUKEMIA & LYMPHOMA, vol.48, no.7, pp.1307-1312, 2007 (SCI-Expanded)
- CLXI. **Mucosa associated lymphoid tissue lymphoma of the sub mandibular gland presenting with relapse in the lacrimal gland**  
KURT M., Shorbagi A., ALTUNDAĞ M. K., AKYÖN YILMAZ Y., DİZDAR Ö., GÜLLÜ İ. H.  
Leukemia, vol.47, pp.1982-1984, 2006 (SCI-Expanded)
- CLXII. **Coincidence of increased pulmonary artery pressure and patent septum foramen ovate in patients with solid tumors may have a propensity to develop central nervous system metastases**  
Harputluoglu H., Dizdar O., Altundag K.  
MEDICAL HYPOTHESES, vol.67, no.4, pp.996, 2006 (SCI-Expanded)
- CLXIII. **Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma**  
Abali H., Eren O., Dizdar O., Karadag O., Erman M., Yilmaz A., ULUÇ K., Erdem I., Turker A.  
LEUKEMIA & LYMPHOMA, vol.46, no.12, pp.1825-1828, 2005 (SCI-Expanded)
- CLXIV. **Seropositive arthritis in chronic lymphocytic leukemia: a remark on B cell-mediated autoimmunity**  
Onal I., Ozcakar L., Dizdar O., Buyukasik Y., Dundar S.  
RHEUMATOLOGY INTERNATIONAL, vol.25, no.7, pp.569-570, 2005 (SCI-Expanded)
- CLXV. **Orbital metastasis from adenocarcinoma of the colon**  
Dizdar O., Aksoy S., Kilickap S., Yalcin S.  
SOUTHERN MEDICAL JOURNAL, vol.98, no.8, pp.846-847, 2005 (SCI-Expanded)
- CLXVI. **Group B streptococcal facet joint arthritis - Case report**  
Dizdar O., Alyamac E., Onal I., Uzun O.

- SPINE, vol.30, no.14, 2005 (SCI-Expanded)
- CLXVII. **Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia**  
Dizdar O., Yurekli B., Purnak T., Aksu S., Haznedaroglu I.  
ANNALS OF PHARMACOTHERAPY, vol.38, pp.1319-1320, 2004 (SCI-Expanded)
- CLXVIII. **Membranoproliferative glomerulonephritis associated with type 1 diabetes mellitus and Hashimoto's thyroiditis**  
Dizdar O., Kahraman S., Genctoy G., Ertoy D., Arici M., Altun B., Yasavul U., Turgan C.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.19, no.4, pp.988-989, 2004 (SCI-Expanded)
- CLXIX. **Obesity: an endocrine tumor?**  
Dizdar O., Alyamac E.  
MEDICAL HYPOTHESES, vol.63, no.5, pp.790-792, 2004 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab**  
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S.  
Journal of Immunotherapy and Precision Oncology, vol.6, no.4, pp.170-176, 2023 (Scopus)
- II. **Smoker Relatives of Inpatients: A Reasonable but Heterogeneous Target Population for Smoking Cessation Program**  
AKTAŞ B. Y., HÜSEYİN B., YÜCE D., DİZDAR Ö., ERMAN M., HAYRAN M., CELİK I.  
Archives of Basic and Clinical Research, vol.5, no.1, pp.178-184, 2023 (Peer-Reviewed Journal)
- III. **Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**  
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.  
Journal of Oncological Science, vol.9, no.1, pp.33-37, 2023 (Scopus)
- IV. **Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience**  
DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., Karakas Y., Kilickap S., Kars A., Turker A., et al.  
SOUTH ASIAN JOURNAL OF CANCER, vol.11, pp.287-292, 2022 (ESCI)
- V. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**  
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.  
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
- VI. **Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA, PTEN and RET mutations in solid tumors**  
Sahin I., Saat H., AKSOY S., DİZDAR Ö., Erdem H. B., Bahsi T.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.16, no.1, 2022 (ESCI)
- VII. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**  
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.  
Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)
- VIII. **Turkish society of medical oncology covid-19 pandemic advisory board updated recommendations for medical oncologists: Included vaccination**  
Sümbül A. T., YALÇIN S. S., ÖZET A., ÜNAL S., DİZDAR Ö., AKBULUT H., KARAOĞLU A., Karadurmuş N., ŞENDUR M. A. N., Çilbir E., et al.  
Journal of Oncological Science, vol.7, no.1, pp.1-6, 2021 (Scopus)
- IX. **Burnout syndrome during residency in internal medicine and pediatrics in a country without**

### **working time directive**

YAZGAN AKSOY D., DURUSU TANRIÖVER M., ÜNAL S., DİZDAR Ö., KALYONCU U., KARAKAYA KARABULUT J., KALE G.

International Journal of Health Care Quality Assurance, 2014 (Scopus)

### **X. Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature**

Tapan U., DİZDAR Ö., Bulut N., ÇELİK İ.

EURASIAN JOURNAL OF MEDICINE, vol.43, no.3, pp.189-191, 2011 (ESCI)

### **XI. Current and emerging treatment options in triple-negative breast cancer**

DİZDAR Ö., Altundag K.

ONCOLOGY REVIEWS, vol.4, no.1, pp.5-13, 2010 (ESCI)

## **Books & Book Chapters**

### **I. Nutrition and Cachexia in Gastrointestinal Cancer Patients**

HALİL M. G., Kuyumcu M. E., DİZDAR Ö., ÜLGER Z., YALÇIN Ş.

in: Textbook of Gastrointestinal Oncology, Yalçın Şuayib, Philip A. Philip, Editor, Springer, pp.379-394, 2019

### **II. esophageal and gastroesophageal junction tumors**

YALÇIN Ş., DİZDAR Ö., KILIÇKAP S., cilbir e., philip p. a.

in: textbook of gastrointestinal oncology, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.55-72, 2019

## **Refereed Congress / Symposium Publications in Proceedings**

### **I. Comprehensive approach focusing on the molecular profile of a rare genodermatosis: Epidermodysplasia Verruciformis**

ERKAN D. D., Akcin O., DURMAZ ÖZDİNÇ C. D., ATEŞ ÖZDEMİR D., GÜLERAY LAFCI N., DİZDAR Ö.

56th Annual Conference of the European-Society-of-Human-Genetics (ESHG), Glasgow, England, 10 - 13 June 2023, pp.397

### **II. Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer**

Bas O., Erdemir A., Onur R., Guner G., Guven D. C., Aksu S., Kertmen N., Aksoy S., Barista I., Turker A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

### **III. Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer**

Ceylan F., Guven D. C., Taban H., Aktepe O., Kilickap S., Turker A., Hamaloglu E., Karakoc D., Isik A., Akyol A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

### **IV. Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days**

Aktas B. Y., Guven D. C., Degirmenciler R. F., Taban H., Aktepe O. H., Kertmen N., Kilickap S., Dizdar O., Aksoy S., Erman M., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

### **V. Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic**

Guven D. C., Ceylan F., Cakir I. Y., Cesmeci E., Sayinalp B., Yesilyurt B., Guner G., Yildirim H. C., Arik Z., Turker A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

### **VI. Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients**

Guven D. C., Aktas B. Y., Aksun M. S., Ucgul E., Sahin T. K., Yildirim H. C., Guner G., Kertmen N., Dizdar O., Kilickap S., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

### **VII. outcomes of patients with resected pancreatic ductal adenocarcinoma**

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., KILIÇKAP S., YALÇIN Ş., DİZDAR Ö.

9th international gastrointestinal cancer conference, 6 - 08 December 2019

- VIII. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**  
Güven D. C., AKTEPE O. H., Berk Z., Güner G., Taban H., AKTAŞ B. Y., Duran Z. C., AKIN Ş., ARIK Z., KERTMEN N., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- IX. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**  
AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Güven D. C., AKTEPE O. H., Güner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- X. **MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?**  
BİLGIN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., YILDIRIM T., ÖZEN S., DİZDAR Ö., HAYRAN K. M., et al.  
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.993
- XI. **Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.**  
Aktas B. Y., Kayku V. E., Aslan A., Kertmen N., Dizdar Ö., Yalcin S., Aksoy S.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XII. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**  
Demir M., Güven D. C., Aktas B. Y., Güner G., Aktepe O. H., Taban H., Kilickap S., Kars A., Turker A., Yalcin S., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XIII. **TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY AND RELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**  
HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., ÇELİK İ.  
ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018, vol.1, pp.11
- XIV. **EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**  
HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., ÇELİK İ.  
ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018
- XV. **Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi**  
GÜVEN D. C., ERGÜNAY K., BRINKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., YILMAZ E., KARAKOÇ D., HAMALOĞLU E., YALÇIN Ş., et al.  
2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018
- XVI. **Compliance to the guideline of diagnostic tests in febrile neutropenic patients at a Turkish university hospital'**  
ZARAKOLU KÖŞKER I. P., AKOVA M., BÜYÜKAŞIK Y., DURUSU TANRIÖVER M., DİZDAR Ö., METAN G., baştuğ z.  
20th Symposium on Infections in the immunocompromised host, Atina, Greece, 17 - 19 June 2018
- XVII. **Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorectal patients and healthy controls. Abst ID:"e15117"**  
GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., LAÇİN Ş., KARAKAŞ Y., KILIÇKAP S., HAYRAN K. M., et al.  
2018 ASCO, Chicago, United States Of America, 1 - 05 June 2018
- XVIII. **Evaluation of cancer risk in patients with periodontal diseases.**  
GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., Baspınar B., AKBIYIK I., AKTAŞ B. Y., YÜCE D., et al.  
2018 ASCO Annual Meeting, Chicago, United States Of America, 1 - 05 June 2018, vol.36, pp.13571
- XIX. **Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi**  
GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., LAÇİN Ş., KARAKAŞ Y.,



KILIÇKAP S., HAYRAN K. M., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018

- XX. **Multimodality treatment in malignant peripheral nerve sheath tumors**  
KARAKAŞ Y., DİZDAR Ö., KÖSEMEHMETOĞLU K., GEDİKOĞLU M. G., SÖYLEMEZOĞLU A. F., BOZBULUT U. B., demir m., KARS S. A., TÜRKER F. A.  
International Congress on oncological sciences, 28 September - 01 October 2017
- XXI. **SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK**  
DİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., BİLGİN E., Hüseyin B., BERKER A. E.  
GAP 2017 Conference, Texas, United States Of America, 9 - 11 May 2017
- XXII. **Using Taylor Regression to Identify Points of Change in Local Cancer Trends**  
HAYRAN K. M., YÜCE D., DİZDAR Ö.  
GAP 2017 CONFERENCE, 9 - 11 May 2017
- XXIII. **Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program**  
AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., HAYRAN K. M., ÇELİK İ.  
7th ECTOH Conference on Tobacco or Health, Porto, Portugal, 22 - 25 March 2017
- XXIV. **Evaluating Admissions of Foreign Patients to a University Hospital in Turkey**  
HAYRAN K. M., YÜCE D., DENEK S., DİZDAR Ö.  
International Forum for Quality Cancer Care, 27 - 29 October 2016
- XXV. **Using geographical information systems to describe quality of life as a function of distance in cancer patients**  
HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., ÇELİK İ.  
ISPOR Asia Pacific Meeting 2016, 3 - 06 September 2016, vol.19, pp.892
- XXVI. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**  
Karakas Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., GÜLLÜ İ. H., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXVII. **Intravenous ferric carboxymaltose treatment in cancer patients**  
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXVIII. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**  
ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., TÜRKER F. A., KARS S. A.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXIX. **Pleomorphic lobular carcinoma of the breast associated with impaired overall survival**  
Hacioglu M. B., Babacan T., Diker O., Akin S., Demir M., Dizdar O., Sendur M. A., Kilickap S., Altundag M. K.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- XXX. **Neuroendocrine breast cancer A single center experience**  
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., DİZDAR Ö., AKSOY S., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXI. **Signet ring cell carcinoma of breast: Single center experience.**  
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXII. **Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.**  
Arik Z., Dizdar O., Yildirim M. E., Ozgu E., Oz M., Terzioglu S. G., Gungor T.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXIII. **Correlation of histopathologic response and prognostic markers with survival in locally advanced**

**non-small cell lung cancer patients who have treated with neoadjuvant chemotherapy.**

Kucukoztas N., Oguz A., Rahatli S., Dizdar O., Keskin G. S. Y., Ozyilkan O., Altundag O.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

- XXXIV. **Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes.**  
Oguz A., Babacan T., Dizdar O., Kucukoztas N., Rahatli S., Keskin G. S. Y., Altundag O., Altundag K.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXXV. **Is there any correlation between molecular subtypes and blood groups in breast cancer?**  
Kucukoztas N., Oguz A., Babacan T., Dizdar O., Rahatli S., Sarici S. F., Keskin G. S. Y., Diker O., Akin S., Altundag O., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXXVI. **Outcomes of patients with endometrial cancer and aggressive histology.**  
Rahatli S., Kucukoztas N., Dizdar O., Dursun P., Yalcin S., Haberal N., Ozen O., Tarhan C., Altundag O., Yildiz F., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXVII. **Impact of treatment strategies on local control and survival in uterine carcinosarcomas.**  
Yalcin S., Dizdar O., Kucukoztas N., Rahatli S., Ozen O., Dursun P., Haberal N., Tarhan C., Yildiz F., Altundag O., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXVIII. **Impact of comorbidities on recurrence rates and survival in patients with endometrial cancer.**  
Kucukoztas N., Dizdar O., Rahatli S., Tarhan C., Haberal N., Dursun P., Yalcin S., Ozen O., Yildiz F., Altundag O., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXIX. **Retrospective analysis of stage IIIc uterine carcinoma patients: A single center experience.**  
Yalcin S., Rahatli S., Kucukoztas N., Ozen O., Haberal N., Tarhan C., Dursun P., Dizdar O., Yildiz F., Altundag O., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XL. **Outcome of breast cancer patients with stage I disease: A retrospective analysis**  
Ergun A., Kucukoztas N., Yalcin S., Rahatli S., Babacan T., Yagmurdu M. C., Ozyilkan O., Dizdar O., Altundag O., Altundag M. K.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XLI. **Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.**  
Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S., Altundag O., Zengin N., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XLII. **Retrospective analysis of stage IC uterine cancer patients: A single center experience.**  
Kucukoztas N., Yalcin S., Rahatli S., Ozen O., Haberal N., Tarhan C., Dursun P., Dizdar O., Yildiz F., Altundag O., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XLIII. **The Frequency and Determinants of Metabolic Syndrome in Patients with Operable Stage I-III Breast Cancer.**  
Aksoy S., Dizdar O., Dede D. S., Arslan C., Dogan E., Tapan U., Ozkan C., Hesenov S., Cinel M., Yaman S., et al.  
32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2009, vol.69
- XLIV. **Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis**  
Dede D. S., Aksoy S., Bulut N., Dizdar O., Arik Z., Gullu I., Ozisik Y., Altundag K.

45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

- XLV. **Zoledronic acid and atrial fibrillation in cancer patients with bone metastases**  
Aksoy S., Dizdar O., Turgut D., Dede D. S., Arslan C., Harputluoglu H., Altundag K.  
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XLVI. **Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis**  
Harputluoglu H., Dizdar O., Aksoy S., Kilickap S., Dede D. S., Ozisik Y., Guler N., Barista I., Gullu I., Selek U., et al.  
30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 13 - 16 December 2007, vol.106
- XLVII. **The correlations of plasma inflammatory markers and anti-nucleosome antibodies with SLEDAI**  
Kalyoncu U., Akdogan A., Calguneri M., Karadag O., Kisacik B., Apras S., Dizdar O., Maras Y., Kiraz S., Ertenli I.  
Annual European Congress of Rheumatology, Vienna, Austria, 8 - 11 June 2005, vol.64, pp.237
- XLVIII. **Biochemical markers of bone turnover in the diagnosis of myeloma bone disease.**  
Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., Tekuzman G.  
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XLIX. **What does determine homocysteine levels in hemodialysis patients: Nutrition or inflammation?**  
Kahraman S., Genctoy G., Yilmaz R., Dizdar O., Arici M., Altun B., Erdem Y., Yasavul U., Turgan C., Caglar S.  
36th Annual Meeting of the American-Society-of-Nephrology, SAN DIEGO, CALIFORNIA, 12 - 17 November 2003, vol.14

## Supported Projects

DİZDAR Ö., ÜNAL S., GÜVEN D. C., GÜLBAHÇE İNCESU F. G., HAYRAN K. M., ERMAN M., AKSOY S., ARIK Z., ALP A., KILIÇKAP S., et al., Project Supported by Higher Education Institutions, COVID19 aşısı uygulanan kanser hastalarında aşının etkinliğinin COVID19 antikor düzeyi ölçülerek değerlendirilmesi, 2021 - 2022

DİZDAR Ö., Ceylan F., AKYOL A., Project Supported by Higher Education Institutions, Pankreas kanserli hastalarda tümörde BRCA1 BRCA2 ve ATM ekspresyonunun kemoterapi yanıtı ve sağ kalım ile ilişkisinin değerlendirilmesi, 2019 - 2020

DİZDAR Ö., Güven D. C., AKDOĞAN KITTANA F. N., ALP A., Project Supported by Higher Education Institutions, Kolon kanseri ile tükürük mikrobiyom ilişkisi, 2017 - 2018

DİZDAR Ö., Project Supported by Higher Education Institutions, "The University of Texas MD Anderson Cancer Center, Global Academic Programs GAP 2017 Conference May 9-11, 2017, Houston, USA" kongresine katılım, 2017 - 2017

ÖZMEN F., ÖZYİĞİT G., DİZDAR Ö., Project Supported by Higher Education Institutions, 11. Hacettepe Üniversitesi Kanser Enstitüsü Onkoloji Sempozyumu, 2015 - 2016

## Metrics

Publication: 232

Citation (WoS): 841

Citation (Scopus): 813

H-Index (WoS): 15

H-Index (Scopus): 14

## Non Academic Experience

